Evaluation of the effect of letrozole in the prevention of ovarian hyperstimulation syndrome

Evaluation of the effect of letrozole in the prevention of ovarian hyperstimulation syndrome in patients at risk of treatment with ovulation-stimulating drugs

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180313039085N1

Enrollment

Registered

2021-04-10

Start date

2020-03-20

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperstimulation of ovaries. Hyperstimulation of ovaries

Interventions

Intervention 1: Intervention group: Five daily doses of recombinant follicle-stimulating hormone 150 Unit/day with Manogan drug 75 Unit/day with Letrozole 5 mg/daily. Intervention 2: Control group: Fi

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Candidate for treatment with ovarian superovulation drugs history of one year of infertility at least Body mass index less than 25 kg/m2 Antimullerian hormone levels higher than 5 ng/ml

Exclusion criteria

Exclusion criteria: History of any hormone therapy during the previous three months History of allergy to letrozole and other aromatase inhibitors History of heart disease History of kidney disease History of liver disease History of endocrine diseases

Design outcomes

Primary

Measure	Time frame
Hyperstimulation of ovaries. Timepoint: Two weeks after starting treatment. Method of measurement: Mild, Moderate, Severe.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeihaneh Asasi

Esfahan University of Medical Sciences

tayebramim@yahoo.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026